Characterization of catechol-thioether-induced apoptosis in human SH-SY5Y neuroblastoma cells

Journal of Neuroscience Research

Volumn 86, Issue 4, 2008, Pages 954-960

  Mosca, Luciana ^a   Tempera, Italo ^a   Lendaro, Eugenio ^a   Di Francesco, Laura ^a   D'Erme, Maria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

5 S cysteinyl dopamine; Catechol thioethers; Neurodegeneration; Parkinson's disease; Programmed cell death

Indexed keywords

5 S CYSTEINYL DOPAMINE; CALCIUM; CASPASE 8; CASPASE 9; CYTOCHROME C; DOPAMINE DERIVATIVE; INDO 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVITY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

EID: 40549122351     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21536     Document Type: Article

References (41)

1. Antkiewicz‐Michaluk L. 2002. Endogenous risk factors in Parkinson's disease: dopamine and tetrahydroisoquinolines. Pol J Pharmacol 54: 567–572.
2. Bates TE, Heales SJ, Davies SE, Boakye P, Clark JB. 1994. Effects of 1‐methyl‐4‐phenylpyridinium on isolated rat brain mitochondria: evidence for a primary involvement of energy depletion. J Neurochem 63: 640–648.
3. Bonnefoy‐Berard N, Genestier L, Flacher M, Revillard JP. 1994. The phosphoprotein phosphatase calcineurin controls calcium‐dependent apoptosis in B cell lines. Eur J Immunol 24: 324–329.
4. Bush WD, Garguilo J, Zucca FA, Albertini A, Zecca L, Edwards GS, Nemanich RJ, Simon JD. 2006. The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface. Proc Natl Acad Sci U S A 103: 14785–15789.
5. Carstam R, Brinck C, Hindemith‐Augustsson A, Rorsman H, Rosengren E. 1991. The neuromelanin of the human substantia nigra. Biochim Biophys Acta 1097: 52–60.
6. Chiba K, Trevor A, Castagnoli N. 1984. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574–578.
7. Chioccara F, Novellino E. 1986. A convenient one step synthesis of 5‐cystein‐S‐yldopa using ceric ammonium nitrate. Synthetic Commun 16: 967–971.
8. Emdadul Haque M, Asanuma M, Higashi Y, Miyazaki I, Tanaka K, Ogawa N. 2003. Apoptosis‐inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim Biophys Acta 1619: 39–52.
9. Fornstedt B, Brun A, Rosengren E, Carlsson A. 1989. The apparent autoxidation rate of catechols in dopamine‐rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm Park Dis Dement Sect 1, 279–295.
10. Grynkiewicz G, Poenie M, Tsien RY. 1985. A new generation of Ca 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440–3450.
11. Hastings TG, Lewis DA, Zigmond MJ. 1996. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci 93: 1956–1961.
12. Izumi Y, Sawada H, Sakka N, Yamamoto N, Kume T, Katsuki H, Shimohama S, Akaike A. 2005. p‐Quinone mediates 6‐hydroxydopamine‐induced dopaminergic neuronal death and ferrous iron accelerates the conversion of p‐quinone into melanin extracellularly. J Neurosci Res 79: 849–860.
13. Kobayashi H, Oikawa S, Kawanishi S. 2006. Mechanism of DNA damage and apoptosis induced by tetrahydropapaveroline, a metabolite of dopamine. Neurochem Res 31: 523–532.
14. Li H, Dryhurst G. 1997. Irreversible inhibition of mitochondrial complex I by 7‐(2‐aminoethyl)‐3,4‐dihydro‐5‐hydroxy‐2H‐1,4‐benzothiazine‐3‐carboxylic acid (DHBT‐1): a putative nigral endotoxin of relevance to Parkinson's disease. J Neurochem 69: 1530–1541.
15. Li H, Dryhurst G. 2001. Oxidative metabolites of 5‐S‐cysteinyldopamine inhibit the pyruvate dehydrogenase complex. J Neural Transm 108: 1363–1374.
16. Means AR. 2000. Regulatory cascades involving calmodulin‐dependent protein kinases. Mol Endocrinol 14: 4–13.
17. Montine KS, Sidell KR, Zhang I, Montine TJ. 2002. Dopamine thioethers: formation in brain and neurotoxicity. Neurotoxicity Res 4: 663–669.
18. Moore DJ, West AB, Dawson VL, Dawson TM. 2005. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28: 57–87.
19. Mosca L, Lendaro E, d'Erme M, Marcellini S, Moretti S, Rosei MA. 2006. 5‐S‐cysteinyl‐dopamine effect on the human dopaminergic neuroblastoma cell line SH‐SY5Y. Neurochem Int 49: 262–269.
20. Nelemans A. 2006. Measurement of [Ca 2+ ] in cell suspensions using indo‐1. Methods Mol Biol 312: 47–53.
21. Nicotera P, Orrenius S. 1998. The role of calcium in apoptosis. Cell Calcium 23: 173–180.
22. Odh G, Carstam R, Paulson J, Wittbjer A, Rosengren E, Rorsman H. 1994. Neuromelanin of the human substantia nigra: a mixed‐type melanin. J Neurochem 62: 2030–2036.
23. Olanow CW, Tatton WG. 1999. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22: 123–144.
24. Pieper AA, Verma A, Zhang J, Snyder SH. 1999. Poly(ADP‐ribose)polymerase, nitric oxide and cell death. TiPS 20: 171–181.
25. Przedborski S, Vila M. 2003. The 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 991: 189–198.
26. Przedborski S, Jackson‐Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G. 2000. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16: 135–142.
27. Salauze L, van der Velden C, Lagroye I, Veyret B, Geffard M. 2005. Circulating antibodies to cysteinyl catecholamines in amyotrophic lateral sclerosis and Parkinson's disease patients. Amyotroph Lateral Scler Other Motor Neuron Disord 6: 226–233.
28. Sarti P, Lendaro E, Ippoliti R, Bellelli A, Benedetti PA, Brunori M. 1999. Modulation of mitochondrial respiration by nitric oxide: investigation by single cell fluorescence microscopy. FASEB J 13: 191–197.
29. Schober A. 2004. Classic toxin‐induced animal models of Parkinson's disease: 6‐OHDA and MPTP. Cell Tissue Res 318: 215–224.
30. Shah GM, Shah RG, Poirier GG. 1996. Different cleavage pattern for poly(ADP‐ribose) polymerase during necrosis and apoptosis in HL‐60 cells. Biochem Biophys Res Commun 229: 838–844.
31. Shen XM, Li H, Dryhurst G. 2000. Oxidative metabolites of 5‐S‐cysteinyldopamine inhibit the a‐ketoglutarate dehydrogenase complex: possible relevance to the pathogenesis of Parkinson's disease. J Neural Transm 107: 959–978.
32. Sidell KR, Amarnath V, Montine TJ. 2001a. Dopamine thioethers in neurodegeneration. Curr Top Med Chem 1: 519–527.
33. Sidell KR, Olson SJ, Ou JJ, Zhang Y, Amarnath V, Montine TJ. 2001b. Cysteine and mercapturate conjugates of oxidized dopamine are in human striatum but only the cysteine conjugate impedes dopamine trafficking in vitro and in vivo. J Neurochem 79: 510–521.
34. Spencer JPE, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B. 1998. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 71: 2112–2122.
35. Spencer JPE, Whiteman M, Jenner P, Halliwell B. 2002. 5‐S‐cysteinyl‐conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase‐3 activity in neurons. J Neurochem 81: 122–129.
36. Takuwa N, Zhou W, Takuwa Y. 1995. Calcium, calmodulin and cell cycle progression. Cell Signal 7: 93–104.
37. Tatton WG, Chalmers‐Redman R, Brown D, Tatton N. 2003. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 53: S61–S72.
38. Vila M, Przedborski S. 2003. Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4: 365–375.
39. Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F, Yang L, Beal MF, Andersen JK. 2001. Caspase‐9 activation results in downstream caspase‐8 activation and bid cleavage in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced Parkinson's disease. J Neurosci 21: 9519–9528.
40. Wang ZB, Liu YQ, Cui YF. 2005. Pathways to caspase activation. Cell Biol Int 29: 489–496.
41. Zucca FA, Giaveri G, Gallorini M, Albertini A, Toscani M, Pezzoli G, Lucius R, Wilms H, Sulzer D, Ito S, Wakamatsu K, Zecca L. 2004. The neuromelanin of human substantia nigra: physiological and pathogenic aspects. Pigment Cell Res 17: 610–617.